Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
March 17, 2026 7:37 AM
Cantor Fitzgerald analyst Kristen Kluska reiterated a Neutral rating and $21.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
